JPMorgan Chase & Co. Issues Pessimistic Forecast for IDEAYA Biosciences (NASDAQ:IDYA) Stock Price

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) had its target price dropped by equities researchers at JPMorgan Chase & Co. from $62.00 to $55.00 in a report released on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 114.34% from the company’s current price.

Other analysts have also issued reports about the company. Jefferies Financial Group reiterated a “buy” rating on shares of IDEAYA Biosciences in a research report on Tuesday, September 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a research report on Tuesday, September 22nd. Truist Financial reiterated a “buy” rating and set a $57.00 target price (down from $59.00) on shares of IDEAYA Biosciences in a research note on Tuesday, November 3rd. Guggenheim decreased their price target on IDEAYA Biosciences from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Wednesday, November 4th. Finally, Wedbush raised their target price on shares of IDEAYA Biosciences from $60.00 to $63.00 and gave the company an “outperform” rating in a research report on Wednesday, November 4th. Fourteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $50.00.

View Our Latest Report on IDEAYA Biosciences

IDEAYA Biosciences Stock Down 1.9%

IDYA traded down $0.51 during trading on Friday, reaching $25.66. 453,683 shares of the company’s stock were exchanged, compared to its average volume of 1,033,991. The company has a market capitalization of $2.48 billion, a P/E ratio of -5.71 and a beta of 0.08. The business has a 50 day moving average price of $34.59 and a 200 day moving average price of $33.79. IDEAYA Biosciences has a fifty-two week low of $25.71 and a fifty-two week high of $42.68.

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.04). IDEAYA Biosciences had a negative return on equity of 39.78% and a negative net margin of 1,157.18%. The company had revenue of $10.24 million during the quarter, compared to analyst estimates of $7.58 million. During the same period in the previous year, the company posted $1.33 earnings per share. The company’s quarterly revenue was up 14.6% on a year-over-year basis. As a group, research analysts forecast that IDEAYA Biosciences will post -4.68 EPS for the current year.

Insider Buying and Selling at IDEAYA Biosciences

In other IDEAYA Biosciences news, CEO Yujiro Hata sold 26,338 shares of the stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $37.41, for a total transaction of $985,304.58. Following the completion of the transaction, the chief executive officer directly owned 690,695 shares of the company’s stock, valued at approximately $25,838,899.95. This represents a 3.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Allworth Financial LP increased its stake in IDEAYA Biosciences by 95.8% in the third quarter. Allworth Financial LP now owns 883 shares of the company’s stock valued at $34,000 after acquiring an additional 432 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of IDEAYA Biosciences during the second quarter valued at approximately $43,000. Sterling Capital Management LLC increased its position in shares of IDEAYA Biosciences by 20.5% during the third quarter. Sterling Capital Management LLC now owns 1,873 shares of the company’s stock valued at $72,000 after buying an additional 319 shares during the period. Nykredit A S bought a new stake in shares of IDEAYA Biosciences during the second quarter valued at approximately $76,000. Finally, GAMMA Investing LLC lifted its position in IDEAYA Biosciences by 79.0% during the 3rd quarter. GAMMA Investing LLC now owns 2,315 shares of the company’s stock valued at $89,000 after acquiring an additional 1,022 shares during the period. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

IDEAYA Biosciences Company Profile

(Get Free Report)

IDEAYA Biosciences, Inc. is a precision oncology company focused on discovering and developing targeted medicines for patients with cancer. Its research uses insights into tumor genetics and synthetic lethality—the idea that certain genetic changes can make cancer cells especially vulnerable to blocking a related biological pathway—to identify potential treatment targets. The company’s investigational pipeline includes small-molecule therapies aimed at specific cancer-related targets. Programs have included darovasertib, a protein kinase C inhibitor being studied in uveal melanoma, and IDE397, a MAT2A inhibitor being developed for tumors with particular genetic alterations.

Further Reading

Analyst Recommendations for IDEAYA Biosciences (NASDAQ:IDYA)

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.